FAAH and Alzheimer disease: Accordingly, targeted pharmacotherapeutic manipulations of eCB signaling have been undertaken in order to attain neuroprotective outcomes; in particular, it may be indirectly enhanced to therapeutic levels through FAAH inhibition, making FAAH an attractive target and selective FAAH inhibitors promising drug candidates for various neurological and neurodegenerative/neuroinflammatory disorders, including AD [16].